from concepts to biomarkers

& innovations in precision medicine

17 research teams,

9 platforms, 3 hosted biotechs

our state-of-the-art tools,

for cancer research

in the heart of a campus dedicated to applied cancer research...

...and Montpellier,

a city historically linked to medical research and teaching

the IRCM research teams
the IRCM research teams

L'Institut de Recherche en Cancérologie de Montpellier :
«Together, let's push the boundaries»

News

SEMINAIRE IRCM

Joffrey PelletierIRB, Barcelone, Espagne"From ribosome control to cancer stem cell biology : new opportunities targeting ribosome biogenesis in colorectal cancer"Contact: laurent.lecam@inserm.fr
En savoir plus

mercredi 15 septembre à 15h, séminaire Mabimprove

Andrew KruseDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School “VHH antibody fragments as tools to interrogate transmembrane receptor signaling”"Research in Dr Kruse's lab aims to elucidate the molecular basis of transmembrane signaling through the use of biochemistry, pharmacological studies, and structural biology. He is particularly interested in signaling pathways with connections to human health and disease, including G protein-coupled receptors and other transmembrane receptors. In the long term, he aims to leverage a detailed molecular understanding of these pathways to facilitate the development of new and better therapeutics." Plus d'informations : https://kruse.hms.harvard.edu/home
En savoir plus

Séminaire IRCM

Daniel Muñoz Cancer Research UK, Cambridge Center“Senotherapy as a novel strategy to prevent lung cancer and treat the advanced disease”Contact: Antonio.maraver@inserm.frMore info: https://www.munoz-espinlab.com
En savoir plus

Séminaire IRCM

Maria CasanovaCNIO, MadridTissue-resident macrophages: helpers of early-stage lung tumor development”Contact : Antonio MaraverMore info: https://www.cnio.es/investigacion-e-innovacion/programas-cientificos/programa-de-oncologia-molecular/grupo-de-inmunidad-del-cancer/  
En savoir plus

Séminaire IRCM

Pablo José FernandezInstituto Madrileño de Estudios Avanzados, Madrid, Espagne "Molecular perspectives of short-term fasting as a nutritional strategy during cancer development and management”More detailshttps://www.food.imdea.org/metabolic-syndrome-group
En savoir plus

Séminaire IRCM

Alejo EfeyanCNIO, Madrid, EspagneNutrient Signaling - Metabolic Driver of Cancer and AgingMore detailshttps://www.cnio.es/en/personas/alejo-efeyan-2/
En savoir plus

Séminaire IRCM

Manuel ColladoSantiago de Compostela University Hospital, Espagne“Cell senescence in development, regeneration and cancer”Contact IRCM : Antonio MARAVERMore detailshttps://stemchus.wordpress.com/lab-members/  
En savoir plus

Postdoctoral Position in Modeling of Drug resistant Lung Cancers Microenvironment

The Colinge Laboratory Cancer Bioinformatics and Systems Biology at IRCM (Cancer Research Institute of Montpellier) is looking for a talented postdoctoral fellow. The microenvironment of cancer cells is known to play an important role in tumor progression and resistance. We are looking for a talented post-doctoral scientist to develop models relating the response to different drugs, e.g. platinum-based, with the microenvironment of lung adenocarcinomas (LUADs). This work will integrate on-going developments to infer the cellular interactions taking place in tumor microenvironments (TMEs), both in single cell transcriptomics and bulk analyses (Cabello et al., 2020; Alame et al., 2020). We aim at establishing quantitative and predictive models of treatment outcome based on data acquired from mouse tumors following different dynamics (rapid/slow growth, spontaneous/acquired resistance, response, etc.). The project involves a consortium of expert laboratories in lung cancer and mouse models thereof, bulk and single cell transcriptomics, animal computer tomography, and 3D-imaging. The postdoc position is funded for 2 years.  More 
En savoir plus

Projet IE 1 an

Publication le 22/03/2021L'équipe "Criblage fonctionnel et ciblage du cancer" recrute un IE débutant pour 1 an sur un projet en collaboration avec l'IRMB et la société MedXCell. La date limite de dépôt des dossiers est le 9 avril à 12h. La description du poste et la procédure de dépôt sont accessibles sur le site https://recrutements.umontpellier.fr/#DETAIL002304
En savoir plus

the word of the director

"Together, let's push the boundaries."

«In just 20 years, the Institut de Recherche en Cancérologie de Montpellier (IRCM U1194) has raised its research to the highest international level in the field of fundamental and applied oncology, research carried out in close collaboration with the clinical departments of the Centre de Lutte Contre le Cancer de Montpellier (ICM: Institut du Cancer de Montpellier), and industrial partners. Jointly operated by Inserm, ICM and the University of Montpellier, the IRCM now brings together more than 200 people, researchers, clinicians, technicians and students, organised into 17 research teams supported by efficient technical platforms and support services. In an extremely competitive and rapidly evolving field of research, our greatest challenge is to stay one step ahead, seek excellence, accelerate innovation and transfer to the patient to ultimately help overcome the countless different forms of cancer.Together, let's push the boundaries.»

Claude Sardet, Director of the IRCM

the word of the director

MAIN PUBLICATIONS

Bousquet Mur E, Bernardo S, Papon L, Mancini M, Fabbrizio E, Goussard M, Ferrer I, Giry A, Quantin X, Pujol J-L, Calvayrac O, Moll H, Glasson Y, Pirot N, Turtoi A, Cañamero M, Wong K-K, Yarden Y, Casanova E, Soria J-C, Colinge J, Siebel C, Favre G, Paz-Ares L, Maraver A Notch inhibition overcomes resistance to Tyrosine Kinase Inhibitors in EGFR-driven lung adenocarcinoma. J. Clin. Invest.. Oct 31, 2019. doi:10.1172/JCI126896

Combes E, Andrade A, Tosi D, Michaud H-A, Coquel F, Desigaud D, Jarlier M, Coquelle A, Pasero P, Bonnefoy N, Martineau P, Del Rio M, Beijersbergen R, Vezzio-Vie N Inhibition of Ataxia-Telangiectasia Mutated and RAD3-related (ATR) overcomes oxaliplatin resistance and promotes anti-tumor immunity in colorectal cancer. Cancer Res.. Apr 15, 2019. doi:10.1158/0008-5472.CAN-18-2807

Ashraf Y, Mansouri H, Laurent-Matha V, Alcaraz L, Roger P, Guiu S, Derocq D, Robin G, Michaud H-A, Jarlier M, Pugnière M, Robert B, Puel A, Martin L, Landomiel F, Bourquard T, Achour O, Fruitier-Arnaudin I, Pichard A, Deshayes E, Turtoi A, Poupon A, Boissière-Michot F, Pirot N, Bernex F, Jacot W, du Manoir S, Theillet C, Pouget J-P, Navarro-Teulon I, Bonnefoy N, Pèlegrin A, Chardès T, Martineau P, Liaudet-Coopman E Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies. J Immunother Cancer. 2019;7(1):29. doi:10.1186/s40425-019-0498-z

Perrot I, Michaud H-A, Giraudon-Paoli M, Augier S, Docquier A, Gros L, Courtois R, Jecko D, Becquart O, Rispaud-Blanc H, Gauthier L, Rossi B, Chanteux S, Gourdin N, Amigues B, Roussel A, Bensussan A, Eliaou J-F, Bastid J, Romagné F, Morel Y, Narni-Mancinelli E, Vivier E, Paturel C, Bonnefoy N Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies. Cell Rep. 2019;27(8):2411-2425.e9. doi:10.1016/j.celrep.2019.04.091

Forest E, Logeay R, Géminard C, Kantar D, Frayssinoux F, Heron-Milhavet L, Djiane A The apical scaffold big bang binds to spectrins and regulates the growth of Drosophila melanogaster wing discs. J. Cell Biol.. 2018;217(3):1047-1062. doi:10.1083/jcb.201705107

Arena G, Cissé M, Pyrdziak S, Chatre L, Riscal R, Fuentes M, Arnold J, Kastner M, Gayte L, Bertrand-Gaday C, Nay K, Angebault-Prouteau C, Murray K, Chabi B, Koechlin-Ramonatxo C, Orsetti B, Vincent C, Marine J-C, Etienne-Manneville S, Bernex F, Lombès A, Cameron C, Dubouchaud H, Ricchetti M, Linares L, Le Cam L Mitochondrial MDM2 Regulates Respiratory Complex I Activity Independently of p53. Mol. Cell. 2018;69(4):594-609.e8. doi:10.1016/j.molcel.2018.01.023

Leconet W, Chentouf M, du Manoir S, Chevalier C, Sirvent A, Aït-Arsa I, Busson M, Jarlier M, Radosevic-Robin N, Theillet C, Chalbos D, Pasquet J-M, Pèlegrin A, Larbouret C, Robert B Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis. Clin. Cancer Res.. 2017;23(11):2806-2816. doi:10.1158/1078-0432.CCR-16-1316

Brustel J, Kirstein N, Izard F, Grimaud C, Prorok P, Cayrou C, Schotta G, Abdelsamie A, Déjardin J, Méchali M, Baldacci G, Sardet C, Cadoret J-C, Schepers A, Julien E Histone H4K20 tri-methylation at late-firing origins ensures timely heterochromatin replication. EMBO J.. 2017;36(18):2726-2741. doi:10.15252/embj.201796541


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés